<p><strong>&lt;&lt;insert slide [1]; 00:00; Note to EA &#8211; Chapter Title: Introductions&gt;&gt;</strong></p>
<p><strong>&lt;&lt;Level 2&gt;&gt; Biotherapeutics: Understanding Immunogenicity for Clinical Practice</strong></p>
<p><strong>&lt;&lt;insert slide [2]; 00:19&gt;&gt;</strong></p>
<p><strong>&lt;&lt;Level 2&gt;&gt; Faculty</strong></p>
<p><strong>&lt;&lt;insert slide [3]; 00:39&gt;&gt;</strong></p>
<p><strong>&lt;&lt;Level 2&gt;&gt; Introduction<sup>[1-5]</sup></strong></p>
<p></p>

<p><strong>&lt;&lt;insert slide [4]; 01:17&gt;&gt;</strong></p>
<p><strong>&lt;&lt;Level 2&gt;&gt; Program Outline</strong></p>
<p></p>

<p><strong>&lt;&lt;insert slide [5]; 01:39; Note to EA &#8211; Chapter Title: ADA Development&gt;&gt;</strong></p>
<p>SOME STUFF</p>

<p><strong>&lt;&lt;insert slide [9]; 06:09; Note to EA &#8211; Chapter Title: Clinical Relevance of ADAs&gt;</strong></p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Impact of ADAs<sup>[6]</sup></strong></p>

<p>&#8226;	The clinical potential of ADAs is primarily within the pharmacokinetics (PK) of the biologic agent</p>

<p>&#8226;	What is relevant is that some patients make only a few molecules/antibodies against the therapeutic agent, resulting is a substantial amount of free drug to be available</p>

<p>&#8226;	In other patients, a large amount of molecules/antibodies are made against the drug complex, resulting in very little effect of the drug; the remaining active concentration may become zero</p>

<p>&#8226;	However, the bottom line is that if there is sufficient drug concentration to obtain the desired therapeutic effect, then the level of immunogenicity that occurs is not relevant</p>

<p>&#8226;	Injection site reactions do occur, but they are usually not mediated by ADAs</p>
